top of page


Sanofi’s Sarclisa Escena Receives FDA Approval as First Oncology Drug Delivered Through On-Body Injector
The FDA has approved Sarclisa Escena, a subcutaneous on-body injector formulation of Sanofi’s multiple myeloma therapy isatuximab, becoming the first cancer treatment authorised in the US for delivery through an on-body injector system. Sanofi has secured US Food and Drug Administration (FDA) approval for Sarclisa Escena, a new subcutaneous (SC) formulation of its multiple myeloma therapy Sarclisa (isatuximab-irfc) delivered through an on-body injector (OBI). The approval rep

nuaxia
Jul 133 min read


FDA Approves Subcutaneous Sarclisa (Isatuximab-Irfc) for Multiple Myeloma Treatment
New formulation expands Sanofi’s Sarclisa portfolio by offering a subcutaneous delivery option across multiple myeloma treatment settings, including newly diagnosed, relapsed and refractory disease.

nuaxia
Jul 103 min read
bottom of page